This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The state’s biotech scene exploded in the mid-2010s and early in the pandemic as exuberant investors disregarded the high failure rate in drugdevelopment and bet on buzzy technologies such as gene editing and messenger RNA vaccines. And although many companies are making layoffs, others are expanding.
How is the industry’s approach to drugdevelopment transforming? How is Waters aiding advancements in drugdevelopment? A central aim in drugdevelopment is to create new molecular entities into commercially viable drugs useful in managing diseases. What are the imperatives that led to this change?
In the marathon of drugdevelopment, where billions of dollars and over a decade of research are the norm, drug repurposing is quietly reshaping the landscape. Challenges in drug repurposing Despite these technological and regulatory advancements, the journey of drug repurposing is not without its challenges.
It is important for all digital healthcare tools to comply with national and supranational data protection legislation governing the processing of patient health data, where legislation falls outside the scope of medicines regulations. As a Non-Clinical Assessor at MHRA he assessed non-clinical data packages for new and genericmedicines.
The US imports a substantial volume of APIs and finished medicines, many of which are essential for patient care, meaning these tariffs could have far-reaching implications. 2 Introducing tariffs on pharmaceutical imports could lead to significant disruptions, particularly for genericmedicines , which often rely on lower-cost API sourcing.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content